Published in Medical Letter on the CDC and FDA, July 31st, 2005
This pivotal trial evaluated the safety and efficacy of the fibrin sealant prepared by the CryoSeal FS System as an adjunct to hemostasis for patients undergoing liver resection surgery. The data will be compiled and included in a PMA (premarket notification) submission expected to be filed in calendar 2005. The review process after a PMA submission typically takes 6 months.
U.S. Food and Drug Administration (FDA) clearance will allow the company to address...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.